Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

Voriconazole N-Oxide (CAS 618109-05-0)

5.0(1)
Write a reviewAsk a question

See product citations (1)

Alternate Names:
(αR,βS)-α-(2,4-Difluorophenyl)-5-fluoro-β-methyl-α-(1H-1,2,4-triazol-1-ylmethyl)-1-oxide-4-pyrimidineethanol
Application:
Voriconazole N-Oxide is a metabolite of voriconazole
CAS Number:
618109-05-0
Molecular Weight:
365.31
Molecular Formula:
C16H14F3N5O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Voriconazole N-Oxide is a derivative of voriconazole, primarily studied for its role in the metabolism and environmental fate of voriconazole, a broad-spectrum antifungal agent. Unlike its parent compound, voriconazole N-oxide is characterized by the addition of an oxygen molecule, forming an N-oxide group. This modification significantly impacts its chemical behavior and biological activity, serving as a marker for the study of drug metabolism pathways and the elucidation of metabolic stability. In research applications, the focus on voriconazole N-oxide helps scientists understand the transformation and degradation processes of antifungal agents in biological systems, including their potential environmental impacts. By investigating the mechanism of action of voriconazole N-oxide, researchers aim to unveil the intricacies of drug metabolism, offering insights into the detoxification processes and the reactivity of drug metabolites. This, in turn, contributes to the broader field of xenobiotic metabolism, providing valuable information for the development of safer and more effective antifungal compounds with minimized environmental footprint.


Voriconazole N-Oxide (CAS 618109-05-0) References

  1. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.  |  Scholz, I., et al. 2009. Br J Clin Pharmacol. 68: 906-15. PMID: 20002085
  2. Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application.  |  Yamada, T., et al. 2012. Clin Biochem. 45: 134-8. PMID: 22138022
  3. Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.  |  Amsden, JR., et al. 2013. Antimicrob Agents Chemother. 57: 3420-3. PMID: 23629717
  4. Steady-state pharmacokinetics and metabolism of voriconazole in patients.  |  Geist, MJ., et al. 2013. J Antimicrob Chemother. 68: 2592-9. PMID: 23766489
  5. Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A.  |  Ona, K. and Oh, DH. 2015. Br J Dermatol. 173: 751-9. PMID: 25919127
  6. Voriconazole metabolism is influenced by severe inflammation: a prospective study.  |  Veringa, A., et al. 2017. J Antimicrob Chemother. 72: 261-267. PMID: 27601292
  7. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.  |  Giri, P., et al. 2017. Eur J Drug Metab Pharmacokinet. 42: 677-688. PMID: 27853934
  8. Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.  |  Hohmann, N., et al. 2017. Br J Clin Pharmacol. 83: 1954-1965. PMID: 28370390
  9. Impact of collagen-induced arthritis on the pharmacokinetic disposition of voriconazole, a widely used antifungal agent: in vitro and in vivo investigations in DBA/1J mice.  |  Giri, P., et al. 2019. Xenobiotica. 49: 698-707. PMID: 29873579
  10. Development and validation of a volumetric absorptive microsampling assay for analysis of voriconazole and voriconazole N-oxide in human whole blood.  |  Moorthy, GS., et al. 2019. J Chromatogr B Analyt Technol Biomed Life Sci. 1105: 67-75. PMID: 30572203
  11. Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.  |  Huang, FR., et al. 2021. Xenobiotica. 51: 1199-1206. PMID: 34402388
  12. Simultaneous Determination of Voriconazole and Its Voriconazole N-Oxide Metabolite in Human Urine by Liquid Chromatography/Tandem Mass Spectrometry.  |  Yu, Y., et al. 2022. J Chromatogr Sci. 60: 800-806. PMID: 34761250
  13. Contribution of voriconazole N-oxide plasma concentration measurements to voriconazole therapeutic drug monitoring in patients with invasive fungal infection.  |  Boglione-Kerrien, C., et al. 2023. Mycoses. 66: 396-404. PMID: 36698317

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Voriconazole N-Oxide, 1 mg

sc-213163
1 mg
$430.00